Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP OTCMKTS:EVTCY NASDAQ:JANX OTCMKTS:NWBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$68.04+2.2%$62.88$52.50▼$77.00$1.44B0.57319,161 shs401,195 shsEVTCYEvotec$4.22+0.5%$4.13$14.22▼$26.57$1.39B0.982,407 shs34,998 shsJANXJanux Therapeutics$27.75+2.8%$24.60$22.48▼$71.71$1.60B2.86875,219 shs859,201 shsNWBONorthwest Biotherapeutics$0.26-1.7%$0.26$0.17▼$0.48$389.67M-1.122.21 million shs2.64 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+2.16%+2.93%+7.40%-1.69%+8.03%EVTCYEvotec+0.48%+1.69%+2.18%+17.22%-11.72%JANXJanux Therapeutics+2.78%+8.36%+21.13%-6.53%-36.80%NWBONorthwest Biotherapeutics-2.60%+17.49%-2.46%-25.57%-33.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.7683 of 5 stars2.51.00.03.32.73.31.3EVTCYEvotecN/AN/AN/AN/AN/AN/AN/AN/AJANXJanux Therapeutics2.1921 of 5 stars3.51.00.00.03.02.50.0NWBONorthwest Biotherapeutics0.0105 of 5 stars0.01.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$78.8815.92% UpsideEVTCYEvotec 0.00N/AN/AN/AJANXJanux Therapeutics 3.08Buy$91.89231.13% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWBO, JANX, ANIP, and EVTCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.007/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.40$7.76 per share8.77$19.11 per share3.56EVTCYEvotec$572.16M2.44$0.04 per share105.53$2.52 per share1.67JANXJanux Therapeutics$10.59M155.05N/AN/A$19.49 per share1.42NWBONorthwest Biotherapeutics$1.38M277.50N/AN/A($0.07) per share-3.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A16.16N/A-3.12%21.35%7.52%8/5/2025 (Estimated)EVTCYEvotec$7.14M$0.4110.29∞N/A20.85%16.02%7.81%N/AJANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)NWBONorthwest Biotherapeutics-$83.78M-$0.07N/A∞N/A-5,757.57%N/A-303.49%8/7/2025 (Estimated)Latest NWBO, JANX, ANIP, and EVTCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A5/15/2025Q1 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.38 million5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98EVTCYEvotec0.532.572.50JANXJanux TherapeuticsN/A58.4758.47NWBONorthwest BiotherapeuticsN/A0.060.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%EVTCYEvotecN/AJANXJanux Therapeutics75.39%NWBONorthwest Biotherapeutics0.04%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%EVTCYEvotecN/AJANXJanux Therapeutics8.10%NWBONorthwest Biotherapeutics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableJANXJanux Therapeutics3059.17 million54.38 millionOptionableNWBONorthwest Biotherapeutics201.46 billion1.33 billionNot OptionableNWBO, JANX, ANIP, and EVTCY HeadlinesRecent News About These CompaniesNWBO - Northwest Biotherapeutics Inc News - MorningstarJuly 11, 2025 | morningstar.comMNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average - Here's WhyJuly 11, 2025 | marketbeat.comNorthwest Biotherapeutics, Inc. (NWBO) - Yahoo FinanceJune 29, 2025 | uk.finance.yahoo.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200 Day Moving Average - Here's WhyJune 25, 2025 | marketbeat.comNWBO Northwest Biotherapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 13, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 11, 2025 | prnewswire.comNorthwest Biotherapeutics: A Spike On Their Expected Imminent ApprovalApril 22, 2025 | seekingalpha.comCitadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)March 29, 2025 | news.bloomberglaw.comNInvestors Watching Two Small-Caps for News on Potential Major Advancements in Cancer TreatmentsJanuary 13, 2025 | msn.comNorthwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional FinancingDecember 26, 2024 | prnewswire.comNorthwest Biotherapeutics: All Is Not Well With This OneDecember 14, 2024 | seekingalpha.comBehind the Bell: Arcutis BiotherapeuticsNovember 5, 2024 | nasdaq.comNorthwest Registered Agent Review 2024: Features, Pricing & MoreOctober 24, 2024 | forbes.com0K95.IL,0P0000AFQ5,0 (0K95.IL)September 14, 2024 | nz.finance.yahoo.comTraders News Digs into the Biotech Space and Releases New Feature ProfileAugust 15, 2024 | br.advfn.comNorthwest Biotherapeutics addresses rumors and market activityAugust 4, 2024 | uk.investing.comNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth OpportunitiesJuly 3, 2024 | prnewswire.comNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual PropertyJune 17, 2024 | prnewswire.comNorthwest Biotherapeutics Inc (NWBO) Dividend HistoryMay 25, 2024 | nasdaq.comNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsMarch 21, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWBO, JANX, ANIP, and EVTCY Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$68.04 +1.44 (+2.16%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$68.12 +0.08 (+0.12%) As of 07/17/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Evotec OTCMKTS:EVTCY$4.22 +0.02 (+0.48%) As of 07/16/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Janux Therapeutics NASDAQ:JANX$27.75 +0.75 (+2.78%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$27.96 +0.22 (+0.77%) As of 07/17/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Northwest Biotherapeutics OTCMKTS:NWBO$0.26 0.00 (-1.73%) As of 07/17/2025 03:59 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
